OncoMethylome Sciences licenses methylation technologies to Qiagen for commercializing epigenetic applications
Herman Spolders, Chief Executive Officer of OncoMethylome Sciences S.A. stated: "We are very pleased to have entered this relationship with QIAGEN, the market leader for sample and assay technologies in molecular diagnostics, applied testing, and pharmaceutical and academic research, which underscores the great value that OncoMethylome's technologies have for the epigenetic cancer research market. The agreement will lead to accelerated research in methylation-based applications for early detection and personalized treatment of cancer."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.